SavedAdd your journal

Journals / Anatolian Journal of Emergency Medicine / 2026 / Cilt: 7 Sayı: 2

Cardiorenal Syndrome

Kardiyorenal Sendrom

Canan Akman(ÇANAKKALE ONSEKİZ MART ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-3427-5649
Pages
97–101
Publication Date
2024-06-29
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although its management is with medical treatment, it can be challenging.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The incidence of heart and kidney diseases together is increasing.
📊
Key Findings & Data:Cardiorenal syndrome (CRS) is defined as an acute and chronic disorder in one organ caused by diseases in the heart and kidney, leading to an acute and chronic disorder in the other organ.
💡
Conclusion & Impact:Although its management is with medical treatment, it can be challenging.
🔬Design:Derleme
📍Scope:Comprehensive Sample
⚙️Variables:Biyobelirteç · böbrek yetmezliği · kalp yetmezliği

Abstract

The incidence of heart and kidney diseases together is increasing. Cardiorenal syndrome (CRS) is defined as an acute and chronic disorder in one organ caused by diseases in the heart and kidney, leading to an acute and chronic disorder in the other organ. CRS involves neurohormonal and hemodynamic mechanisms. There are five subtypes. Although its management is with medical treatment, it can be challenging.

Özet

Son zamanlarda kalp ve böbrek hastalıklarının birlikte görülme sıklığı artmaktadır. Kardiyo-renal sendrom (KRS), kalp ve böbreğin akut ve kronik fonksiyon bozukluğu sonucu çift yönlü akut ve kronik işlev bozukluklarının görüldüğü bir klinik tablodur. Patofizyolojisinde nörohormonal ve hemodinamik mekanizmalar yer almaktadır. Beş alt tipi bulunmaktadır. KRS’nin yönetimi tibbi tedavideki ilerlemelere rağmen halen zorlu olabilmektedir.

🔖

Cite This Article

Akman, C. (2024). Cardiorenal Syndrome. Anatolian Journal of Emergency Medicine, Cilt: 7 Sayı: 2, 97–101. https://doi.org/10.54996/anatolianjem.1412207

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (27)

  1. Prastaro M, Nardi E, Paolillo S, et al. Cardiorenal syndrome: Pathophysiology as a key to the therapeutic approach in an underdiagnosed disease. J Clin Ultrasound. 2022 Oct;50(8): 1110-1124. doi: 10.1002/jcu.23265.
  2. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527-1539. doi:10.1016/j.jacc.2008.07.051.
  3. Ronco C, Di Lullo L. Cardiorenal syndrome in Western countries: epidemiology, diagnosis and management approaches. Kidney Dis (Basel). 2017;2:151–163. doi: 10.1159/000448749
  4. Gallo G, Lanza O, Savoia C. New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy. Int J Mol Sci.2023 Mar 7;24(6):5089 doi: 10.3390/ijms24065089
  5. Kumar U, Garimella PS, Wettersten N. Cardiorenal syndromePathophysiology. Cardiol Clin. 2019 August; 37(3): 251–265. doi:10.1016/j.ccl.2019.04.001.
  6. Gembillo G, Visconti L, Giusti MA, et al. Cardiorenal Syndrome: New Pathways and Novel Biomarkers. Biomolecules 2021, 11, 1581. https://doi.org/10.3390/biom11111581.
  7. Colombo PC, Doran AC, Onat D, et al. Venous congestion, endothelial and neurohormonal activation in acute decompensated heart failure: cause or effect? Curr Heart Fail Rep. 2015;12(3):215–222.
  8. Minami Y, Kajimoto K, Sato N, et al. Effect of Elevated C-Reactive Protein Level at Discharge on Long-Term Outcome in Patients Hospitalized for Acute Heart Failure. Am J Cardiol. 2018;121(8):961–968. doi:10.1016/j.amjcard.2017.12.046.
  9. Palazzuoli A, Antonelli G, Nuti R. Anemia in Cardio-Renal Syndrome: clinical impact and pathophysiologic mechanisms. Heart Fail Rev 2011;16(6):603–607. doi:10.1007/s10741-011-9230-x.
  10. Denton KM, Shweta A, Anderson WP. Preglomerular and postglomerular resistance responses to different levels of sympathetic activation by hypoxia. J Am Soc Nephrol. 2002;13(1):27–34. https://jasn.asnjournals.org/content/13/1/27.
  11. Rangaswami J, Bhalla V, Blair JE, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from theAmerican Heart Association. Circulation 2019;139:e840–e78.
  12. Kim JA, Wu L, Rodriguez M, et al. Recent Developments in the Evaluation and Management of Cardiorenal Syndrome: A Comprehensive Review. Curr Probl Cardiol. 2023 Mar;48(3):101509. doi: 10.1016/j.cpcardiol.2022.101509.
  13. Rangaswami J, Bhalla V, Blair JEA, et al. American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation.2019 Apr 16;139(16):e840-e878. doi: 10.1161/CIR.0000000000000664.
  14. Georgopoulou T, Petrakis I, Dermitzaki K, et al. Cardiorenal Syndrome: Challenges in Everyday Clinical Practice and Key Points towards a Better Management. J Clin Med. 2023 Jun 18;12(12):4121. doi: 10.3390/jcm12124121.
  15. Kirklin JK, Naftel DC, Kormos RL, et al. Fifth Intermacs annual report: Risk factor analysis from more than 6.000 mechanical circulatory support patients. J of Heart and Lung Transplant. 2013;32(2). http://dx.doi.org/10.1016/j.healun.2012.12.004
  16. Thind G.S., Loehrke M., Wilt J.L. Acute cardiorenal syndrome: Mechanisms and clinical implications. Clevel. Clin J Med. 2018;85:231–239. doi: 10.3949/ccjm.85a.17019.
  17. Mullens W, Dauw J, Martens P, et al. Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): Baseline characteristics. Eur J Heart Fail. 2022;24:1601–1610. doi: 10.1002/ejhf.2587.
  18. Tang WHW, Kiang A. Acute Cardiorenal Syndrome in Heart Failure: From Dogmas to Advances. Curr Cardiol Rep. 2020;22:143. doi: 10.1007/s11886-020-01384-0.
  19. Shulenberger CE, Jiang A, Devabhakthuni S,et al. Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance. Pharmacotherapy. 2016;36:852–860. doi: 10.1002/phar.1798.
  20. Verbrugge FH, Martens P, Ameloot K, et al. Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome. Acta Cardiol. 2019;74:100–107. doi: 10.1080/00015385.2018.1455947.
  21. Butler J, Anstrom KJ, Felker GM, et al. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. JAMA Cardiol. 2017;2:950–958. doi: 10.1001/jamacardio.2017.2198.
  22. Singh A, Laribi S, Teerlink JR,et al. Agents with vasodilator properties in acute heart failure. Eur Heart J 2017;38:317–325. doi: 10.1093/eurheartj/ehv755.
  23. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs Dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. JAMA. 2007;297:1883–1891. doi: 10.1001/jama.297.17.1883.
  24. Packer M, Colucci W, Fisher L,et al. Effect of Levosimendan on the Short-Term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1:103–111. doi: 10.1016/j.jchf.2012.12.004.
  25. Testani JM, Kimmel SE, Dries DL, et al. Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail. 2011;4:685–691. doi: 10.1161/CIRCHEARTFAILURE.111.963256.
  26. Kumar U, Garimella PS, Wettersten N. Cardiorenal syndromePathophysiology. Cardiol Clin. 2019 August; 37(3): 251–265. doi:10.1016/j.ccl.2019.04.001.
  27. Georgopoulou T, Petrakis I, Dermitzaki K, et al. Cardiorenal Syndrome: Challenges in Everyday Clinical Practice and Key Points towards a Better Management. J Clin Med. 2023 Jun 18;12(12):4121. doi: 10.3390/jcm12124121.